Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 2
2004 1
2006 2
2009 1
2010 3
2011 5
2012 3
2013 1
2014 9
2015 15
2016 12
2017 13
2018 13
2019 5
2020 8
2021 17
2022 9
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

103 results

Results by year

Filters applied: . Clear all
Page 1
Peginterferon Beta.
[No authors listed] [No authors listed] 2023 Aug 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2023 Aug 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 29999831 Free Books & Documents. Review.
After a standard subcutaneous dose of peginterferon beta-1a, the amount of peginterferon beta 1a in milk is miniscule. ...Polyethylene glycol is not excreted into breastmilk.[1] Many women have breastfed while taking conventional interfer …
After a standard subcutaneous dose of peginterferon beta-1a, the amount of peginterferon beta 1a i …
Peginterferon beta-1a concentrations in breast milk of lactating multiple sclerosis patients.
Houtchens M, Mahlanza T, Ciplea AI, Manieri MC, Ramia NF, Zhao Y, England S, Avila R, Altincatal A, Vignos M, Hellwig K. Houtchens M, et al. Mult Scler Relat Disord. 2022 Apr;60:103700. doi: 10.1016/j.msard.2022.103700. Epub 2022 Feb 20. Mult Scler Relat Disord. 2022. PMID: 35263702
We examined concentrations of peginterferon beta-1a in breast milk of lactating patients with multiple sclerosis (MS) receiving peginterferon beta-1a as their postpartum disease-modifying therapy. METHODS: After completion of titration to …
We examined concentrations of peginterferon beta-1a in breast milk of lactating patients with multiple sclerosis (MS) r …
Peginterferon beta-1a: a review of its use in patients with relapsing-remitting multiple sclerosis.
Hoy SM. Hoy SM. CNS Drugs. 2015 Feb;29(2):171-9. doi: 10.1007/s40263-015-0227-1. CNS Drugs. 2015. PMID: 25666445 Review.
In ADVANCE, peginterferon beta-1a had an acceptable tolerability profile that was consistent with that of established interferon beta treatments. ...In the absence of head-to-head studies, definitive conclusions on the comparative efficacy and tolerability of …
In ADVANCE, peginterferon beta-1a had an acceptable tolerability profile that was consistent with that of established i …
Global Peginterferon Beta-1a Tolerability Management Best Practices: A Nurse-Focused Delphi Approach.
White S, Harris C, Allan M, Chieffe C, Eelen P, Röder C, Mouzawak C, Naylor ML. White S, et al. Neurol Ther. 2021 Jun;10(1):251-263. doi: 10.1007/s40120-021-00238-3. Epub 2021 Mar 24. Neurol Ther. 2021. PMID: 33761099 Free PMC article.
INTRODUCTION: Injection site reactions (ISRs) and flu-like symptoms (FLS) are common in patients with relapsing forms of multiple sclerosis (MS) treated with peginterferon beta-1a. The purpose of this Delphi analysis was to explore peginterferon bet …
INTRODUCTION: Injection site reactions (ISRs) and flu-like symptoms (FLS) are common in patients with relapsing forms of multiple sclerosis …
Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE.
Kieseier BC, Arnold DL, Balcer LJ, Boyko AA, Pelletier J, Liu S, Zhu Y, Seddighzadeh A, Hung S, Deykin A, Sheikh SI, Calabresi PA. Kieseier BC, et al. Mult Scler. 2015 Jul;21(8):1025-35. doi: 10.1177/1352458514557986. Epub 2014 Nov 28. Mult Scler. 2015. PMID: 25432952 Free PMC article. Clinical Trial.
METHODS: Patients were randomized to placebo or 125 g peginterferon beta-1a every 2 or 4 weeks. For Year 2 (Y2), patients originally randomized to placebo were re-randomized to peginterferon beta-1a every 2 weeks or every 4 weeks. Patient …
METHODS: Patients were randomized to placebo or 125 g peginterferon beta-1a every 2 or 4 weeks. For Year 2 (Y2), patien …
Pharmacokinetics/pharmacodynamics by race: Analysis of a peginterferon beta-1a phase 1 study.
Zhao Y, Mokliatchouk O, Ramia NF, Naylor ML, Butts CL. Zhao Y, et al. Med. 2022 Sep 9;3(9):612-621.e3. doi: 10.1016/j.medj.2022.06.006. Epub 2022 Jul 18. Med. 2022. PMID: 35853458 Free article. Clinical Trial.
METHODS: Peginterferon beta-1a (125 mug) was administered by subcutaneous or intramuscular injection, followed by a washout period before a second injection using the alternative method. ...CONCLUSIONS: No clinically meaningful differences were identified bet …
METHODS: Peginterferon beta-1a (125 mug) was administered by subcutaneous or intramuscular injection, followed by a was …
Peginterferon beta-1a was associated with high adherence and satisfaction in patients with multiple sclerosis in a German real-world study.
Menge T, Rehberg-Weber K, Taipale K, Nastos I, Jauß M. Menge T, et al. Ther Adv Neurol Disord. 2021 Mar 19;14:17562864211000461. doi: 10.1177/17562864211000461. eCollection 2021. Ther Adv Neurol Disord. 2021. PMID: 33796146 Free PMC article.
Adult patients with RRMS (previously treated or treatment-naive) receiving peginterferon beta-1a (125 g SC every 2 weeks) were eligible for participation. ...Clinical disease activity remained low. Peginterferon beta-1a was well tolerated …
Adult patients with RRMS (previously treated or treatment-naive) receiving peginterferon beta-1a (125 g SC every 2 week …
Peginterferon beta-1a reduces disability worsening in relapsing-remitting multiple sclerosis: 2-year results from ADVANCE.
Newsome SD, Kieseier BC, Liu S, You X, Kinter E, Hung S, Sperling B. Newsome SD, et al. Ther Adv Neurol Disord. 2017 Jan;10(1):41-50. doi: 10.1177/1756285616676065. Epub 2016 Nov 16. Ther Adv Neurol Disord. 2017. PMID: 28450894 Free PMC article.
METHODS: In total, 1512 patients were randomized to placebo or peginterferon beta-1a 125 mcg every 2 or 4 weeks. After 1 year, patients on placebo were re-randomized to peginterferon beta-1a every 2 or 4 weeks. ...Benefits were maintained …
METHODS: In total, 1512 patients were randomized to placebo or peginterferon beta-1a 125 mcg every 2 or 4 weeks. After …
103 results